Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
8
×
genentech
8
×
life sciences
national blog main
biotech
national top stories
boston blog main
boston top stories
clinical trials
national
san francisco blog main
san francisco top stories
eli lilly
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
gene therapy
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
cancer
celgene
glaxosmithkline
johnson & johnson
medical device
novartis
What
fda
bio
roundup
drug
new
roche
approved
cancer
drugs
known
medicine
news
regulatory
therapy
acquire
agreed
appetite
approval
atrophy
august
big
billion
biopharma
biotech
black
blueprint
bread
broad
busy
butter
buyout
candidate
cash
chemistry
cmc
companies
confidence
congress
congressional
consistent
Language
unset
Current search:
genentech
×
fda
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine